[go: up one dir, main page]

NO20001601L - Genterapitilnærminger for Õ tilføre apolipoprotein A-1- agonister og deres anvendelse for Õ behandle dyslipidemiske forstyrrelser - Google Patents

Genterapitilnærminger for Õ tilføre apolipoprotein A-1- agonister og deres anvendelse for Õ behandle dyslipidemiske forstyrrelser

Info

Publication number
NO20001601L
NO20001601L NO20001601A NO20001601A NO20001601L NO 20001601 L NO20001601 L NO 20001601L NO 20001601 A NO20001601 A NO 20001601A NO 20001601 A NO20001601 A NO 20001601A NO 20001601 L NO20001601 L NO 20001601L
Authority
NO
Norway
Prior art keywords
apoa
agonists
apolipoprotein
native
inject
Prior art date
Application number
NO20001601A
Other languages
English (en)
Other versions
NO20001601D0 (no
Inventor
Jean-Louis Dasseux
Renate Sekul
Klaus Buttner
Isabelle Cornut
Gunther Metz
Jean Dufourcq
Original Assignee
Dasseux Jean Louis
Renate Sekul
Klaus Buttner
Isabelle Cornut
Gunther Metz
Jean Dufourcq
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dasseux Jean Louis, Renate Sekul, Klaus Buttner, Isabelle Cornut, Gunther Metz, Jean Dufourcq filed Critical Dasseux Jean Louis
Publication of NO20001601D0 publication Critical patent/NO20001601D0/no
Publication of NO20001601L publication Critical patent/NO20001601L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/775—Apolipopeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Physics & Mathematics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • Optics & Photonics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

Oppfinnelsen relateres til genetiske tilnærminger for å tilføre nukleotidsekvenser som. koder for modifiserte former av de native formene til apolipoprotein A-I (ApoA-1):. modent ApoA-I, preproApoA-I og proApoA-I; inkludert nativt ApoÅ-I sorii er ;~;>--- \ modifisert til å inneholde ApoA-I agonister, peptider som etterligner aktiviteten til ApoA-I; ApoA-I superagonister, peptider som overgår aktiviteten til nativt ApoA-I; og modifisert nativt ApoA-I som har én eller flere amfipatiske helikser byttet ut med nukleotidsekvensene til én eller flere ApoA-I agonister; for behandlingen av forstyrrelser som er assosiert med dyslipoprotcincmi, innbefattende kardiovaskulær sykdom, aterosklerose, restenose, hyperlipidemi og andre forstyrrelser som septisk sjokk.
NO20001601A 1997-09-29 2000-03-28 Genterapitilnærminger for Õ tilføre apolipoprotein A-1- agonister og deres anvendelse for Õ behandle dyslipidemiske forstyrrelser NO20001601L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/940,136 US6518412B1 (en) 1997-09-29 1997-09-29 Gene therapy approaches to supply apolipoprotein A-I agonists and their use to treat dyslipidemic disorders
PCT/US1998/020329 WO1999016409A2 (en) 1997-09-29 1998-09-28 Gene therapy approaches to supply apolipoprotein a-i agonists and their use to treat dyslipidemic disorders

Publications (2)

Publication Number Publication Date
NO20001601D0 NO20001601D0 (no) 2000-03-28
NO20001601L true NO20001601L (no) 2000-05-26

Family

ID=25474297

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20001601A NO20001601L (no) 1997-09-29 2000-03-28 Genterapitilnærminger for Õ tilføre apolipoprotein A-1- agonister og deres anvendelse for Õ behandle dyslipidemiske forstyrrelser

Country Status (17)

Country Link
US (4) US6518412B1 (no)
EP (1) EP1039934B1 (no)
JP (1) JP2003525565A (no)
KR (1) KR100650975B1 (no)
CN (1) CN100345588C (no)
AT (1) ATE323510T1 (no)
AU (1) AU758307B2 (no)
CA (1) CA2304814A1 (no)
DE (1) DE69834267T2 (no)
ES (1) ES2263221T3 (no)
HU (1) HU225821B1 (no)
IL (1) IL135324A0 (no)
NO (1) NO20001601L (no)
NZ (1) NZ503720A (no)
PL (1) PL193662B1 (no)
RU (1) RU2222545C2 (no)
WO (1) WO1999016409A2 (no)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6004925A (en) * 1997-09-29 1999-12-21 J. L. Dasseux Apolipoprotein A-I agonists and their use to treat dyslipidemic disorders
US6518412B1 (en) * 1997-09-29 2003-02-11 Jean-Louis Dasseux Gene therapy approaches to supply apolipoprotein A-I agonists and their use to treat dyslipidemic disorders
JP4794707B2 (ja) * 1998-11-17 2011-10-19 ソニー株式会社 端末装置、課金システム、データ処理方法
CA2402772A1 (en) * 2000-03-13 2001-09-20 Amgen Inc. Apolipoprotein-a-i regulation of t-cell signalling
US7148197B2 (en) * 2000-08-24 2006-12-12 The Regents Of The University Of California Orally administered small peptides synergize statin activity
US6664230B1 (en) * 2000-08-24 2003-12-16 The Regents Of The University Of California Orally administered peptides to ameliorate atherosclerosis
US7199102B2 (en) * 2000-08-24 2007-04-03 The Regents Of The University Of California Orally administered peptides synergize statin activity
US7723303B2 (en) * 2000-08-24 2010-05-25 The Regents Of The University Of California Peptides and peptide mimetics to treat pathologies characterized by an inflammatory response
US8568766B2 (en) 2000-08-24 2013-10-29 Gattadahalli M. Anantharamaiah Peptides and peptide mimetics to treat pathologies associated with eye disease
US7144862B2 (en) * 2000-08-24 2006-12-05 The Regents Of The University Of California Orally administered peptides to ameliorate atherosclerosis
US7166578B2 (en) 2000-08-24 2007-01-23 The Regents Of The University Of California Orally administered peptides synergize statin activity
US7470659B2 (en) * 2001-12-07 2008-12-30 The Regents Of The University Of California Methods to increase reverse cholesterol transport in the retinal pigment epithelium (RPE) and Bruch's membrane (BM)
US6930085B2 (en) 2002-04-05 2005-08-16 The Regents Of The University Of California G-type peptides to ameliorate atherosclerosis
US7959659B2 (en) * 2004-01-02 2011-06-14 Advanced Cardiovascular Systems, Inc. High-density lipoprotein coated medical devices
US20060205669A1 (en) * 2004-09-16 2006-09-14 The Regents Of The University Of California G-type peptides and other agents to ameliorate atherosclerosis and other pathologies
CA2584048C (en) 2004-10-15 2016-08-09 Alan T. Remaley Multi-domain amphipathic helical peptides and methods of their use
CN101115496B (zh) 2004-12-06 2012-03-07 加州大学评议会 改善微动脉的结构和功能的方法
US20080293639A1 (en) * 2005-04-29 2008-11-27 The Regents Of The University Of California Peptides and peptide mimetics to treat pathologies characterized by an inflammatory response
MX2008015337A (es) * 2006-06-01 2009-11-26 Inst Cardiologie Montreal Metodo y compuesto para el tratamiento de estenosis valvular.
US20080206142A1 (en) * 2006-06-16 2008-08-28 Lipid Sciences, Inc. Novel Peptides That Promote Lipid Efflux
US20080227686A1 (en) * 2006-06-16 2008-09-18 Lipid Sciences, Inc. Novel Peptides that Promote Lipid Efflux
WO2007149355A2 (en) * 2006-06-16 2007-12-27 Lipid Sciences, Inc. Novel peptides that promote lipid efflux
US20110002962A1 (en) * 2006-08-17 2011-01-06 The Uab Research Foundation Immunogenic PcpA Polypeptides and Uses Thereof
US20080138284A1 (en) * 2006-09-26 2008-06-12 Lipid Sciences, Inc. Novel Peptides That Promote Lipid Efflux
DK2195331T3 (da) * 2007-08-28 2014-02-03 Uab Research Foundation Syntetiske polypeptider, der efterligner apolipoprotein e, og anvendelsesmetoder
WO2009032702A2 (en) 2007-08-28 2009-03-12 Uab Research Foundation Synthetic apolipoprotein e mimicking polypeptides and methods of use
US7985727B1 (en) 2007-09-20 2011-07-26 Abbott Cardiovascular Systems Inc. Apo A-I mimetic peptides and methods of treatment
US8101565B2 (en) * 2007-09-20 2012-01-24 Abbott Cardiovascular Systems Inc. Sustained release of Apo A-I mimetic peptides and methods of treatment
US9173890B2 (en) 2007-09-20 2015-11-03 Abbott Cardiovascular Systems Inc. Sustained release of Apo A-I mimetic peptides and methods of treatment
US7985728B1 (en) 2007-09-20 2011-07-26 Abbott Cardiovascular Systems Inc. Sustained release of Apo A-I mimetic peptides and methods of treatment
US8044021B2 (en) * 2007-09-20 2011-10-25 Abbott Cardiovascular Systems Inc. Sustained release of apo A-I mimetic peptides and methods of treatment
WO2009129263A1 (en) * 2008-04-15 2009-10-22 The Government Of The Usa As Represented By The Secretary Of The Department Of Health & Human Serv. Peptides promoting lipid efflux via abca1 and activating a lipoprotein lipase
EP2396017B1 (en) * 2009-02-16 2015-07-01 Cerenis Therapeutics Holding SA Apolipoprotein a-i mimics
US8176412B2 (en) * 2009-08-25 2012-05-08 International Business Machines Corporation Generating formatted documents
US9187550B2 (en) 2010-08-30 2015-11-17 Hoffman—La Roche Inc. Tetranectin-apolipoprotein A-I, lipid particles containing it and its use
EP4400511A3 (en) 2011-02-07 2024-09-04 Abionyx Pharma SA Lipoprotein complexes and manufacturing and uses thereof
US9592268B2 (en) 2011-05-23 2017-03-14 Cornell University Endothelium protective materials and methods of use
MX2014001920A (es) 2011-08-25 2014-04-14 Hoffmann La Roche Proteina de fusion acortada de tetranectina-apolipoproteina a-i, una particula lipidica que la contiene, y usos de la misma.
CN104250288B (zh) * 2013-06-28 2018-02-27 清华大学 两亲性α螺旋自组装肽及其应用
BR112016025470A2 (pt) 2014-05-02 2017-08-15 Cerenis Therapeutics Holding S A ?hdl terapêutico?
US10653747B2 (en) 2014-07-31 2020-05-19 Uab Research Foundation ApoE mimetic peptides and higher potency to clear plasma cholesterol
EP3471778A4 (en) * 2016-06-20 2020-02-19 The Regents of The University of Michigan COMPOSITIONS AND METHODS FOR ADMINISTERING BIOMACROMOLECULAR AGENTS

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH621479A5 (no) 1977-08-05 1981-02-13 Battelle Memorial Institute
CA1173360A (en) 1979-06-22 1984-08-28 Jurg Schrank Pharmaceutical preparations
DE3241102A1 (de) 1982-11-06 1984-05-10 A. Nattermann & Cie GmbH, 5000 Köln Imidazolylalkylthienyl-tetrahydropyridazine und verfahren zu ihrer herstellung
US4643988A (en) 1984-05-15 1987-02-17 Research Corporation Amphipathic peptides
US4880635B1 (en) 1984-08-08 1996-07-02 Liposome Company Dehydrated liposomes
US4857319A (en) 1985-01-11 1989-08-15 The Regents Of The University Of California Method for preserving liposomes
ATE171192T1 (de) 1992-06-12 1998-10-15 Innogenetics Nv Peptide und proteine, verfahren zur ihren herstellung und die verwendung als cholesterol- annehmer
US5674855A (en) 1992-08-12 1997-10-07 The Rogosin Institute Methods and compositions useful in prophylaxis and therapy of endotoxin related conditions
SE9203753D0 (sv) 1992-12-11 1992-12-11 Kabi Pharmacia Ab Expression system for producing apolipoprotein ai-m
US5643757A (en) * 1994-03-21 1997-07-01 American Cyanamid Company High yield production of human apolipoprotein A1 in E. coli.
WO1995027512A2 (en) * 1994-04-11 1995-10-19 Baylor College Of Medicine Compositions and methods for gene therapy to treat disease
FR2734568B1 (fr) 1995-05-22 1997-06-20 Rhone Poulenc Rorer Sa Nouveaux variants de l'apolipoproteine
US6518412B1 (en) * 1997-09-29 2003-02-11 Jean-Louis Dasseux Gene therapy approaches to supply apolipoprotein A-I agonists and their use to treat dyslipidemic disorders

Also Published As

Publication number Publication date
DE69834267T2 (de) 2007-01-04
AU758307B2 (en) 2003-03-20
NZ503720A (en) 2002-10-25
JP2003525565A (ja) 2003-09-02
NO20001601D0 (no) 2000-03-28
EP1039934A1 (en) 2000-10-04
EP1039934B1 (en) 2006-04-19
HU225821B1 (en) 2007-10-29
US20080050351A1 (en) 2008-02-28
PL193662B1 (pl) 2007-03-30
CN1303298A (zh) 2001-07-11
ATE323510T1 (de) 2006-05-15
KR20010030806A (ko) 2001-04-16
IL135324A0 (en) 2001-05-20
KR100650975B1 (ko) 2006-11-29
US20030208059A1 (en) 2003-11-06
PL358529A1 (en) 2004-08-09
US20050148513A1 (en) 2005-07-07
EP1039934A4 (en) 2002-11-27
WO1999016409A2 (en) 1999-04-08
US7250407B2 (en) 2007-07-31
HUP0003924A2 (hu) 2001-01-29
US6518412B1 (en) 2003-02-11
CN100345588C (zh) 2007-10-31
AU9671498A (en) 1999-04-23
RU2222545C2 (ru) 2004-01-27
DE69834267D1 (de) 2006-05-24
HUP0003924A3 (en) 2005-12-28
US6844327B2 (en) 2005-01-18
CA2304814A1 (en) 1999-04-08
ES2263221T3 (es) 2006-12-01

Similar Documents

Publication Publication Date Title
NO20001601L (no) Genterapitilnærminger for Õ tilføre apolipoprotein A-1- agonister og deres anvendelse for Õ behandle dyslipidemiske forstyrrelser
BG101115A (en) Hanipulation of protoporphyrinogen oxidase enzyme activity in eukaryotic organisms
EP1003379A4 (en) NEW PHYTASE
BR9810248A (pt) Sequências reguladoras para plantas transgênicas.
WO1999053040A3 (de) Menschliche nukleinsäuresequenzen aus ovartumorgewebe
GB0202556D0 (en) Novel Protein
ATE404217T1 (de) Therapie mit lipoproteinlipase (lpl) variant
ATE307886T1 (de) Nukleotidsequenzen, proteine, medikamente und diagnoseagentien zur anwendung in krebsbehandlung
PT851926E (pt) Variantes do interferao-gama (rhu-ifn-gama) recombinante humano com estabilidade termica melhorada
DE69736276D1 (de) Menschliche dnase resistent gegen actininhibitoren
EP0815233A4 (en) NEW CYTOKININE FROM BIRDS AND CODING GENETIC SEQUENCES THEREFOR
WO1999046374A3 (de) Menschliche nukleinsäuresequenzen aus prostatatumorgewebe
DK1222294T3 (da) Promotor til regulering af ekspression af fremmede gener
ATE278014T1 (de) Target zur behandlung von atherosklerose, fettleibigkeit und diabetis typ ii
DE60238333D1 (de) Auf antibiotikum basierendes genregulationssystem
WO1999046375A3 (de) Menschliche nukleinsäuresequenzen aus prostatagewebe
PL1711612T3 (pl) Kasety ekspresyjne do dwukierunkowej ekspresji transgenicznej kwasów nukleinowych w roślinach
WO1999042137A3 (en) Stress promoter control of therapeutic genes in gene therapy: compositions and methods
BR9910703A (pt) Processo para produzir uma cepa thy a- do vibrio cholerae, cepa thy a- do vibrio cholerae, sequências de nucleotìdeo de um gene thy a do vibrio cholerae e de uma região de flanque 5' e 3' de um gene estrutural gene thy a do vibrio cholerae, proteìna, e, vacina
ATE226446T1 (de) Muteine von wildtyp-cytokinen und ihre verwendung als immunogene
Sgambati et al. Cytotoxic activity of chimeric protein PD-L4UWSCItr does not appear be affected by specificity of inhibition mediated by anti-protease WSCI domain
CN104177487A (zh) 一种利用原核表达系统制备神经生长抑制因子重组蛋白的方法
DE60319333D1 (de) Hitzelabile Desoxyribonuklease I-Varianten
WO2005094415A3 (en) Recombinant vectors and methods for inducing an immune response
Chong Synoviolin and rheumatoid arthritis